Duncker Streett & Co’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
SDH
EP
Duncker Streett & Co's ARKG Position: Q1 2021 in Review
Duncker Streett & Co sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2021, closing a stake of 125 shares — an estimated $12K sold.
Duncker Streett & Co first reported a position in ARKG in Q4 2020 and held it in 1 quarter. The position peaked at $12K in Q4 2020. 505 funds tracked by Wall St. Rank hold ARKG as of Q1 2021.
- Duncker Streett & Co reported no remaining ARK Genomic Revolution ETF position as of Q1 2021 after selling out during the quarter.
- Duncker Streett & Co sold 125 ARK Genomic Revolution ETF shares in Q1 2021, an estimated $12K.
- Duncker Streett & Co first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 1 quarter.
- Duncker Streett & Co's ARK Genomic Revolution ETF position peaked at $12K in Q4 2020.
- 505 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2021.
Based on Duncker Streett & Co's 13F filing for Q1 2021, filed 28 Apr 2021.